Fulgent Genetics EBITDA Margin 2015-2024 | FLGT
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Fulgent Genetics (FLGT) over the last 10 years. The current EBITDA margin for Fulgent Genetics as of September 30, 2024 is .
| Fulgent Genetics EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2024-09-30 | $0.28B | $-0.07B | -24.46% |
| 2024-06-30 | $0.29B | $-0.05B | -17.53% |
| 2024-03-31 | $0.29B | $-0.05B | -17.71% |
| 2023-12-31 | $0.29B | $-0.05B | -18.28% |
| 2023-09-30 | $0.29B | $-0.05B | -18.47% |
| 2023-06-30 | $0.31B | $-0.05B | -15.26% |
| 2023-03-31 | $0.37B | $-0.01B | -3.01% |
| 2022-12-31 | $0.62B | $0.22B | 34.89% |
| 2022-09-30 | $0.80B | $0.40B | 49.56% |
| 2022-06-30 | $0.93B | $0.55B | 59.68% |
| 2022-03-31 | $0.95B | $0.63B | 66.35% |
| 2021-12-31 | $0.99B | $0.69B | 69.89% |
| 2021-09-30 | $1.04B | $0.77B | 73.94% |
| 2021-06-30 | $0.91B | $0.67B | 73.08% |
| 2021-03-31 | $0.77B | $0.57B | 73.09% |
| 2020-12-31 | $0.42B | $0.29B | 69.67% |
| 2020-09-30 | $0.14B | $0.07B | 48.89% |
| 2020-06-30 | $0.04B | $0.00B | 9.30% |
| 2020-03-31 | $0.03B | $0.00B | 5.88% |
| 2019-12-31 | $0.03B | $0.00B | 6.45% |
| 2019-09-30 | $0.03B | $0.00B | 6.90% |
| 2019-06-30 | $0.03B | 0 | 0.00% |
| 2019-03-31 | $0.02B | $-0.00B | -4.55% |
| 2018-12-31 | $0.02B | $-0.00B | -9.09% |
| 2018-09-30 | $0.02B | $-0.00B | -20.00% |
| 2018-06-30 | $0.02B | $-0.01B | -26.32% |
| 2018-03-31 | $0.02B | $-0.01B | -26.32% |
| 2017-12-31 | $0.02B | $-0.00B | -10.53% |
| 2017-09-30 | $0.02B | $0.00B | 9.52% |
| 2017-06-30 | $0.02B | $0.00B | 14.29% |
| 2017-03-31 | $0.02B | $0.00B | 20.00% |
| 2016-12-31 | $0.02B | $0.00B | 16.67% |
| 2016-06-30 | $0.01B | $0.00B | 20.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.520B | $0.289B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $8.497B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $5.276B | 164.53 |
| Hims & Hers Health (HIMS) | United States | $5.141B | 130.72 |
| Privia Health (PRVA) | United States | $2.533B | 211.10 |
| Enovis (ENOV) | United States | $2.529B | 17.15 |
| IRhythm Technologies (IRTC) | United States | $2.362B | 0.00 |
| Azenta (AZTA) | United States | $2.001B | 99.78 |
| Omnicell (OMCL) | United States | $1.964B | 64.26 |
| Clover Health Investments (CLOV) | United States | $1.644B | 0.00 |
| 10x Genomics (TXG) | United States | $1.643B | 0.00 |
| Schrodinger (SDGR) | United States | $1.378B | 0.00 |
| Phreesia (PHR) | United States | $1.072B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.650B | 0.00 |
| Standard BioTools (LAB) | United States | $0.562B | 0.00 |
| Talkspace (TALK) | United States | $0.522B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.483B | 83.60 |
| Health Catalyst (HCAT) | United States | $0.459B | 0.00 |
| TruBridge (TBRG) | United States | $0.244B | 71.22 |
| Pulmonx (LUNG) | United States | $0.237B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.214B | 0.00 |
| American Well (AMWL) | United States | $0.122B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.107B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.075B | 0.00 |
| HeartBeam (BEAT) | United States | $0.067B | 0.00 |
| 111 (YI) | China | $0.053B | 0.00 |
| CareCloud (CCLD) | United States | $0.046B | 0.00 |
| Zepp Health (ZEPP) | China | $0.040B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.040B | 0.00 |
| Outset Medical (OM) | United States | $0.039B | 0.00 |
| Movano (MOVE) | United States | $0.020B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.019B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.012B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.010B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.004B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |